Skip to main content
Pharmadrug Inc. logo

Pharmadrug Inc. — Investor Relations & Filings

Ticker · PHRX ISIN · CA71716W2040 LEI · 529900PHQPAWL5ITEB39 CSE Manufacturing
Filings indexed 475 across all filing types
Latest filing 2022-11-28 Regulatory Filings
Country CA Canada
Listing CSE PHRX

About Pharmadrug Inc.

https://pharmadrug.ca/

Pharmadrug Inc. is a specialty pharmaceutical company focused on the research, development, and commercialization of controlled-substances and natural medicines. The company's primary focus areas include the clinical development of reformulated natural-based medicines aimed at treating unmet needs in oncology and infectious diseases. Additionally, Pharmadrug develops synthetic and biosynthetic formulations of existing drugs, specifically addressing opportunities related to the potential third wave of drug policy reform concerning controlled substances.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2022-11-28 English
Management information circular - English.pdf
Regulatory Filings
2022-11-03 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the completion of cGMP drug substance manufacturing for a pharmaceutical product (PD-001) and describing ongoing clinical development programs, preclinical study results, and regulatory interactions with the FDA. It includes detailed information about drug development progress, clinical trial plans, and scientific data supporting the drug's potential. There is no indication that this is a formal regulatory filing such as an Annual Report, Interim Report, or Earnings Release. It is not a transcript, proxy, or voting result announcement. The document is a corporate announcement focused on operational and development milestones rather than financial results or governance changes. Given the detailed nature and length (15,000 characters), it is not a brief announcement or a report publication notice. The content fits best as a Capital/Financing Update (CAP) because it relates to progress in drug manufacturing and development, which are key operational updates relevant to investors and capital markets, often classified under CAP filings for pharmaceutical companies.
2022-10-04 English
Notice.pdf
Regulatory Filings
2022-09-09 English
Notice of the meeting and record date - English.pdf
Regulatory Filings
2022-09-08 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2022-08-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.